DEA Cannabis Rescheduling Hearing Nears End After Two-Week Proceedings
The DEA's marijuana rescheduling hearing concludes July 15th after featuring government witnesses and seven prohibitionist groups over 14 days of testimony.
The Drug Enforcement Administration's formal hearing on cannabis rescheduling enters its final day tomorrow, marking the end of a two-week proceeding that began June 29th. The hearing addresses the Notice of Proposed Rulemaking to move marijuana from Schedule I to Schedule III under the Controlled Substances Act, representing the most significant federal cannabis policy shift in decades.
The hearing structure reveals the contentious nature of rescheduling, with government witnesses testifying on the opening day before seven prohibitionist organizations dominated the remaining sessions. This allocation suggests the DEA faces substantial opposition to the Biden administration's rescheduling initiative, which emerged from a comprehensive Health and Human Services review concluding cannabis meets Schedule III criteria.
Rescheduling would eliminate the 280E tax provision that prevents cannabis companies from deducting standard business expenses, potentially adding hundreds of millions in cash flow across the industry. Multi-state operators like Curaleaf, Green Thumb Industries, and Cresco Labs stand to benefit most significantly, with effective tax rates currently exceeding 70% in many cases due to 280E restrictions.
The hearing's focus on prohibitionist testimony indicates rescheduling faces more resistance than markets initially anticipated. While the scientific evidence supporting medical cannabis use has strengthened considerably since the original Schedule I classification, entrenched opposition from law enforcement and anti-drug organizations continues to influence federal policy discussions.
The DEA will now review all testimony and public comments before issuing its final rule. Cannabis equity valuations remain compressed compared to other consumer sectors, trading at significant discounts despite strong operational performance. The rescheduling timeline and final implementation details will determine whether the industry can access traditional banking services and institutional capital that have remained largely unavailable under current federal restrictions.